TRCT
KROS icon

Tower Research Capital (TRC)’s Keros Therapeutics KROS Stock Holding History

Tower Research Capital (TRC)’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Sell
1,966
-732
-27% -$8.15K ﹤0.01% 3509
2026
Q1 		$29.8K Buy
2,698
+860
+47% +$13.3K ﹤0.01% 3177
2025
Q4 		$37.4K Sell
1,838
-285
-13% -$5K ﹤0.01% 2645
2025
Q3 		$33.6K Sell
2,123
-1,030
-33% -$15.2K ﹤0.01% 2844
2025
Q2 		$42.1K Buy
3,153
+1,888
+149% +$25.5K ﹤0.01% 3118
2025
Q1 		$12.9K Sell
1,265
-21,719
-94% -$252K ﹤0.01% 3416
2024
Q4 		$364K Buy
22,984
+21,145
+1,150% +$1.1M 0.01% 1274
2024
Q3 		$107K Sell
1,839
-3,084
-63% -$152K ﹤0.01% 2177
2024
Q2 		$225K Buy
4,923
+4,028
+450% +$216K ﹤0.01% 1971
2024
Q1 		$59.2K Sell
895
-7,367
-89% -$437K ﹤0.01% 2161
2023
Q4 		$328K Buy
8,262
+7,625
+1,197% +$239K ﹤0.01% 1708
2023
Q3 		$20.3K Sell
637
-1,329
-68% -$49.6K ﹤0.01% 3357
2023
Q2 		$79K Buy
1,966
+826
+72% +$36.2K ﹤0.01% 2225
2023
Q1 		$48K Buy
1,140
+654
+135% +$33K ﹤0.01% 2530
2022
Q4 		$23K Sell
486
-2,357
-83% -$110K ﹤0.01% 2997
2022
Q3 		$107K Sell
2,843
-789
-22% -$27.3K ﹤0.01% 2508
2022
Q2 		$100K Buy
3,632
+3,255
+863% +$143K ﹤0.01% 2296
2022
Q1 		$21K Sell
377
-1,300
-78% -$66.7K ﹤0.01% 3488
2021
Q4 		$98K Buy
1,677
+1,193
+246% +$59.5K ﹤0.01% 2231
2021
Q3 		$19K Sell
484
-526
-52% -$18.7K ﹤0.01% 3759
2021
Q2 		$43K Buy
1,010
+448
+80% +$24.3K ﹤0.01% 3146
2021
Q1 		$35K Buy
562
+370
+193% +$23.4K ﹤0.01% 3423
2020
Q4 		$14K Sell
192
-6,207
-97% -$391K ﹤0.01% 4099
2020
Q3 		$247K Buy
6,399
+6,052
+1,744% +$240K ﹤0.01% 2371
2020
Q2 		$13K Buy
+347
New +$10.7K ﹤0.01% 3901

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Tower Research Capital (TRC)'s KROS Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Keros Therapeutics (KROS) stake by 27% in Q2 2026, selling an estimated $8.15K and leaving 1,966 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #3509.

Tower Research Capital (TRC) first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $364K in Q4 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Tower Research Capital (TRC) held 1,966 shares of Keros Therapeutics worth $21K as of Q2 2026.
  • Tower Research Capital (TRC) sold 732 Keros Therapeutics shares in Q2 2026, an estimated $8.15K.
  • Keros Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3509 holding.
  • Tower Research Capital (TRC) first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Keros Therapeutics position peaked at $364K in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.